With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight
When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention. | At the Senate committee hearing on Novo Nordisk's prices for Ozempic and Wegovy,
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...
A U.S. Senate panel criticized Novo Nordisk for the high prices of Ozempic and Wegovy. Novo Nordisk CEO blamed high prices on ...
At the hearing, Novo CEO Lars Fruergaard Jørgensen said the company would consider new talks with insurers about the list prices of Wegovy and Ozempic if they follow through on a pledge to keep ...
Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...
WASHINGTON—U.S. Senator Mike Braun questioned Novo Nordisk CEO, Lars Fruergaard Jørgensen, at the Senate Health, Education, ...
Novo Nordisk chief executive Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the health care costs of the ...
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback